Johannes Fruehauf is Executive Director of LabCentral, a new shared lab facility in Kendall Square, Cambridge, Massachusetts. He is also the founder of Cambridge BioLabs (CBL), a contract research facility servicing startup and virtual companies in Kendall Square. CBL specializes in the development of startup ideas and validation of scientific concepts and helps investors make informed decisions before larger amounts of capital are deployed. The experience at CBL resulted in the joint development of the LabCentral concept. He is a serial biotech entrepreneur, a co-founder of ViThera Pharmaceuticals, Deltix, and Cequent Pharmaceuticals, and an advisor or Board member to numerous life sciences companies and non-profits. Dr. Fruehauf is the author of over 20 peer reviewed publications and named inventor on nine patents related to RNA interference and bacterial therapeutics.